Member Info for milktrayman69

Hey 81 lucky , was there any recent news around Coopers and this product that I have missed in terms of them reporting back on their sales/product launches etc around Eroxon to give this impression? Dont follow FUM as much as i used to

Ok so ...here we go....what's the future for this company then

Either it's been mismanagement by barder and co or the product is just not flying off shelves.

As an investor I fully believed in the product and thought the product would speak for itself and gloss over the mismanagement .

When you have the likes of haleon on board and Cooper's you would say that they were not suckers and believed like us.

Anyway let's see the sales figures , that will tell a story but however I am glad to see the back of barder and co and happy to see lombard on board and the new chap who seems to have a lot of industry experience behind him

Let's wait and see ....could be case of the company being primed for a takeover who knows. We unfortunately have no choice but to wait and see as a lot of us are in this knees deep since the early days topping up over the years

What does this all mean for Uk investors on LSE, are our shares now worth nothing , or are they planning to cancel them? Can we still trade on LSE with them or have they been transferred to the NASDAQ market, meaning that we still own shares and just have to trade on Nasdaq?

Https://news.cision.com/navamedic-asa/r/navamedic-q4-and-full-year-2024--continued-growth-in-a-year-with-investments-in-new-growth-initiativ,c4104125

Some news for you lot:

https://news.cision.com/navamedic-asa/r/navamedic-q4-and-full-year-2024--continued-growth-in-a-year-with-investments-in-new-growth-initiativ,c4104125

https://navamedic.com/news/navamedic-launches-eroxon-in-finland/

https://navamedic.com/news/navamedic-asa-launches-eroxon/

Some news maybe from last year launches

Unfortunately of no fault of anyone on this forum we have now resorted to conspiracy theories and speculation here in the absence of as always vague and unambiguous RNS statements by the BOD . How can anyone running this company s be taken serious with the stunts they have done for the last few years , you have a product that works albeit on 60% of recipients and world class distributors as partners , how can you F**k up so bad with your forecasting and comms to shareholders ? You have distributors who are advertising on major sporting events in the US and well respected distributors in Europe yet you still manage to tank the share price with your elementary mistakes!!

My shares portfolio are currently are dire viewing, this was my hero stock and the BOD seem to always grab defeat from the jaws of victory. How do they manage it is beyond me , they seriously need to let someone else manage the Pr of this company. How can they retract on their forecasts so much going from profit to loss in the space of months is beyond me .

Happy New Year fellow investors , I hope this is the year that we really start to see some gains on this stock . Performance has been underwhelming , even though all the boxes are being ticked . The market really wants to see tangible sales figures i guess before they part with money to see the progress of this product, of which i am not sure how FUM board will present ?

Waiting for this share to explode , based on stream of good news we have had , including the most recent of new products about to start the lifecycle of testing . Sexual dysfunctional over the counter product fro females is surely a worlds first!!!

Fumsters ,do we genuinely believe that the negative reviews on Amazon and Boots are foul play by other parties? Interested on your honest thoughts

Surf, how was this update shared to you , via email ?

Well i guess this depends on what FUM consider good performance for their BOD. and how their performance is measured.Currently i am not sure what we are looking for, for the next leg up, apart from positive news to come out of haleon on sales of Eroxon as FUM seem to not be forthcoming . We may hear of more launches of the product in different regions but i cannot see that move the sp up currently.

Albeit it seems that FUM prefer the partner model for partners to do the legwork and are more interested in grooming potential future partners than investors at the moment

It seems to be of late that we are at the mercy of institutional investors on this one currently which i find quite surprising considering the publicity this product has had in public forums . Putting aside CFO and CEO ability to sell themselves or to sell the opportunity to the wider world . I would be lining up interviews and hiring a PR firm to shout from the rooftops the opportunity and getting in bed with Ann Summers ; )

Regardless, I'm still scratching my head to the reaction of the market on this week's announcements and news coming out of FUM.

Yes it is unfortunate 81Lucky , as the saying goes they seem to "snatch defeat form the jaws of victory" every time they put out a financial update . I don't think we are being harsh here , but FUM BOD do not do themselves a favour by being lacklustre and generic with their figures. I am hoping they take on some of the feedback that they have been given by investors on how they present themselves. We are beyond a R+D company now as they control the manufacturing , so they should act accordingly as a producer of the worlds first erectile dysfunction .

I do love Do's and Don't post in describing Barder, made my laugh first thing in the morning!! "He only brings death and disaster" LOL

Some good info shared today here, I noticed that the product was not mentioned on haleon corporate website but splattered all over their haleon partner website

My Target price has always been £1+ , I did expect the share price to be a lot higher tbh on the news of the US launch . I guess the market needs convincing on numbers i guess?

Https://news.cision.com/navamedic-asa/r/navamedic-q1-2024--successful-product-launch-and-steady-operational-progress,c3970410

FYI :

“The successful launch in Norway of Eroxon® in February was an important and significant event. After only two weeks in the market, this clinically proven local treatment of erectile dysfunction was the bestseller at an online pharmacy. Strong sales in the rest of the first quarter, resulted in Eroxon® ranking third on Navamedic’s most sold products in the Consumer Health segment. Eroxon® will be launched in Sweden in May, and in Finland later this year,” said Kathrine Gamborg, CEO of Navamedic ASA.

https://news.cision.com/navamedic-asa/r/navamedic-q1-2024--successful-product-launch-and-steady-operational-progress,c3970410